Literature DB >> 19492897

Morphology and in vitro infectivity of sporozoites of Cryptosporidium parvum.

Franz Petry1, Inka Kneib, J Robin Harris.   

Abstract

An important obstacle in studying Cryptosporidium parvum is the lack of a permanent in vitro cultivation system of the parasite. While short-term cultures using various host cell lines have been widely employed, long-term cultures that would facilitate the immortalization of C. parvum isolates have not yet been developed. The description of the complete development of C. parvum in cell-free culture in 2004 has been received with great interest and also with some astonishment. Unfortunately, attempts to reproduce these results with different isolates of C. parvum and also C. hominis have failed. In this report, we provide an alternative interpretation of the nature of a parasite stage that occurs 24 hr after excystation of oocysts which, morphologically, is similar to stages that have been regarded as being extracellular trophozoites or merozoites by other investigators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19492897     DOI: 10.1645/GE-2021.1

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  3 in total

1.  Glycoproteins and Gal-GalNAc cause Cryptosporidium to switch from an invasive sporozoite to a replicative trophozoite.

Authors:  Adam Edwinson; Giovanni Widmer; John McEvoy
Journal:  Int J Parasitol       Date:  2015-09-30       Impact factor: 3.981

Review 2.  Organoids and Bioengineered Intestinal Models: Potential Solutions to the Cryptosporidium Culturing Dilemma.

Authors:  Samantha Gunasekera; Alireza Zahedi; Mark O'Dea; Brendon King; Paul Monis; Benjamin Thierry; Jillian M Carr; Una Ryan
Journal:  Microorganisms       Date:  2020-05-11

Review 3.  Past and future trends of Cryptosporidium in vitro research.

Authors:  Alexander J Bones; Lyne Jossé; Charlotte More; Christopher N Miller; Martin Michaelis; Anastasios D Tsaousis
Journal:  Exp Parasitol       Date:  2018-12-03       Impact factor: 2.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.